RU2406724C2 - Конденсированные трициклические соединения в качестве ингибиторов фактора некроза опухоли альфа - Google Patents
Конденсированные трициклические соединения в качестве ингибиторов фактора некроза опухоли альфа Download PDFInfo
- Publication number
- RU2406724C2 RU2406724C2 RU2007121682/04A RU2007121682A RU2406724C2 RU 2406724 C2 RU2406724 C2 RU 2406724C2 RU 2007121682/04 A RU2007121682/04 A RU 2007121682/04A RU 2007121682 A RU2007121682 A RU 2007121682A RU 2406724 C2 RU2406724 C2 RU 2406724C2
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- compound
- hydrogen
- formula
- methyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract 80
- 206010054094 Tumour necrosis Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims abstract 109
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 61
- 239000001257 hydrogen Substances 0.000 claims abstract 61
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 33
- 229910052736 halogen Chemical group 0.000 claims abstract 29
- 150000002367 halogens Chemical group 0.000 claims abstract 29
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims abstract 27
- 150000002431 hydrogen Chemical group 0.000 claims abstract 26
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims abstract 17
- 150000003839 salts Chemical class 0.000 claims abstract 16
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims abstract 13
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 13
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract 13
- 238000000034 method Methods 0.000 claims abstract 11
- 125000005842 heteroatom Chemical group 0.000 claims abstract 9
- 125000005129 aryl carbonyl group Chemical group 0.000 claims abstract 8
- 239000003814 drug Substances 0.000 claims abstract 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims abstract 6
- 230000000694 effects Effects 0.000 claims abstract 6
- 125000004043 oxo group Chemical group O=* 0.000 claims abstract 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 5
- 230000002401 inhibitory effect Effects 0.000 claims abstract 5
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract 5
- 229910052760 oxygen Chemical group 0.000 claims abstract 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract 4
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 claims abstract 4
- 125000002950 monocyclic group Chemical group 0.000 claims abstract 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims abstract 4
- 239000001301 oxygen Chemical group 0.000 claims abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 3
- -1 [1,4] diazepanyl Chemical group 0.000 claims 28
- 125000004193 piperazinyl group Chemical group 0.000 claims 10
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 9
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 9
- 239000002253 acid Substances 0.000 claims 8
- 150000004702 methyl esters Chemical class 0.000 claims 8
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 7
- 238000006243 chemical reaction Methods 0.000 claims 7
- 125000003282 alkyl amino group Chemical group 0.000 claims 6
- 125000003277 amino group Chemical group 0.000 claims 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 6
- 230000002159 abnormal effect Effects 0.000 claims 5
- 125000001309 chloro group Chemical group Cl* 0.000 claims 5
- 241000124008 Mammalia Species 0.000 claims 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 230000007062 hydrolysis Effects 0.000 claims 4
- 238000006460 hydrolysis reaction Methods 0.000 claims 4
- 150000002828 nitro derivatives Chemical class 0.000 claims 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 3
- 239000000460 chlorine Substances 0.000 claims 3
- 229910052801 chlorine Inorganic materials 0.000 claims 3
- 230000001684 chronic effect Effects 0.000 claims 3
- 230000004968 inflammatory condition Effects 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 229910052717 sulfur Chemical group 0.000 claims 3
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 2
- 125000003830 C1- C4 alkylcarbonylamino group Chemical group 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 claims 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- 206010061598 Immunodeficiency Diseases 0.000 claims 2
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 2
- 208000001132 Osteoporosis Diseases 0.000 claims 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 2
- 206010040070 Septic Shock Diseases 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- 201000009961 allergic asthma Diseases 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 2
- 229910052794 bromium Inorganic materials 0.000 claims 2
- 208000019069 chronic childhood arthritis Diseases 0.000 claims 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 230000001747 exhibiting effect Effects 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 239000011737 fluorine Substances 0.000 claims 2
- 230000007813 immunodeficiency Effects 0.000 claims 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 238000006396 nitration reaction Methods 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 230000001590 oxidative effect Effects 0.000 claims 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims 2
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 239000011593 sulfur Chemical group 0.000 claims 2
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 201000003874 Common Variable Immunodeficiency Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 206010014824 Endotoxic shock Diseases 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- 208000007452 Plasmacytoma Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 241000534944 Thia Species 0.000 claims 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 150000001923 cyclic compounds Chemical class 0.000 claims 1
- HJZOOZBCIXESNA-UHFFFAOYSA-N cycloheptane dihydrochloride Chemical compound C1CCCCCC1.Cl.Cl HJZOOZBCIXESNA-UHFFFAOYSA-N 0.000 claims 1
- ZKNJGYBHKGDNCD-UHFFFAOYSA-N cycloheptane;hydrochloride Chemical compound Cl.C1CCCCCC1 ZKNJGYBHKGDNCD-UHFFFAOYSA-N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 125000006316 iso-butyl amino group Chemical group [H]N(*)C([H])([H])C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- GXHMMDRXHUIUMN-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O.CS(O)(=O)=O GXHMMDRXHUIUMN-UHFFFAOYSA-N 0.000 claims 1
- WRTMOQVDBQDRNW-UHFFFAOYSA-N methyl 10-chloro-1-methyl-8-piperazin-1-yl-6h-benzo[b][1,5]benzoxathiepine-3-carboxylate;hydrochloride Chemical compound Cl.C1=C2CSC3=CC(C(=O)OC)=CC(C)=C3OC2=C(Cl)C=C1N1CCNCC1 WRTMOQVDBQDRNW-UHFFFAOYSA-N 0.000 claims 1
- 230000003647 oxidation Effects 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- RFIOZSIHFNEKFF-UHFFFAOYSA-N piperazine-1-carboxylic acid Chemical compound OC(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-N 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 238000007363 ring formation reaction Methods 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 239000010802 sludge Substances 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 230000005951 type IV hypersensitivity Effects 0.000 claims 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 102000009270 Tumour necrosis factor alpha Human genes 0.000 abstract 1
- 108050000101 Tumour necrosis factor alpha Proteins 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
- C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/39—Heterocyclic compounds having sulfur as a ring hetero atom having oxygen in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1226MU2004 | 2004-11-10 | ||
| IN1226/MUM/2004 | 2004-11-10 | ||
| US63721704P | 2004-12-17 | 2004-12-17 | |
| US60/637,217 | 2004-12-17 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2007121682A RU2007121682A (ru) | 2008-12-20 |
| RU2406724C2 true RU2406724C2 (ru) | 2010-12-20 |
Family
ID=38654748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007121682/04A RU2406724C2 (ru) | 2004-11-10 | 2005-11-08 | Конденсированные трициклические соединения в качестве ингибиторов фактора некроза опухоли альфа |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US7834052B2 (enExample) |
| EP (1) | EP1812419A2 (enExample) |
| JP (1) | JP2008519824A (enExample) |
| KR (1) | KR20070106981A (enExample) |
| CN (1) | CN101076525B (enExample) |
| AR (1) | AR056861A1 (enExample) |
| AU (1) | AU2005303410B2 (enExample) |
| CA (1) | CA2587671A1 (enExample) |
| IL (2) | IL183038A0 (enExample) |
| MX (1) | MX2007005470A (enExample) |
| NZ (1) | NZ554937A (enExample) |
| RU (1) | RU2406724C2 (enExample) |
| TW (1) | TW200615273A (enExample) |
| WO (1) | WO2006051477A2 (enExample) |
| ZA (1) | ZA200703712B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8709999B2 (en) | 2009-03-27 | 2014-04-29 | Presidio Pharmaceuticals, Inc. | Substituted bicyclic HCV inhibitors |
| IN2012DN01684A (enExample) | 2009-08-27 | 2015-06-05 | U S A Represented By The Secretary Dept Of Health And Human Services | |
| WO2011075375A1 (en) * | 2009-12-14 | 2011-06-23 | Schering Corporation | Fused tricyclic compounds for the treatment of inflammatory disorders |
| JP5697685B2 (ja) * | 2009-12-18 | 2015-04-08 | バジリア ファルマスーチカ アーゲーＢａｓｉｌｅａ Ｐｈａｒｍａｃｅｕｔｉｃａ ＡＧ | 三環式抗生物質 |
| US8822520B2 (en) | 2010-09-22 | 2014-09-02 | Presidio Pharmaceuticals, Inc. | Substituted bicyclic HCV inhibitors |
| US8999967B2 (en) | 2010-09-29 | 2015-04-07 | Presidio Pharmaceuticals, Inc. | Tricyclic fused ring inhibitors of hepatitis C |
| GB201507903D0 (en) * | 2015-05-08 | 2015-06-24 | Oncopeptides Ab | Process for preparation of nitrogen mustard derivatives |
| CN106995382A (zh) * | 2016-01-25 | 2017-08-01 | 济南和润化工科技有限公司 | 一种催化氢化法生产3-甲基-4-氨基苯甲酸的方法 |
| WO2017167993A1 (en) * | 2016-04-01 | 2017-10-05 | Ucb Biopharma Sprl | Fused pentacyclic imidazole derivatives as modulators of tnf activity |
| CA3019245A1 (en) * | 2016-04-01 | 2017-10-05 | Ucb Biopharma Sprl | Fused pentacyclic imidazole derivatives as modulators of tnf activity |
| CN109219609B (zh) * | 2016-04-01 | 2022-02-01 | Ucb生物制药私人有限公司 | 作为tnf活性调节剂的稠合六环咪唑衍生物 |
| WO2017167996A1 (en) * | 2016-04-01 | 2017-10-05 | Ucb Biopharma Sprl | Fused pentacyclic imidazole derivatives as modulators of tnf activity |
| CN106831460A (zh) * | 2017-02-24 | 2017-06-13 | 青铜峡市嘉华化工有限公司 | 3‑甲基‑4‑氨基苯甲酸的制备方法 |
| USD817148S1 (en) * | 2017-04-05 | 2018-05-08 | Dormakaba Canada Inc. | Locking system housing |
| CN107501106A (zh) * | 2017-08-14 | 2017-12-22 | 中涛新材料有限公司 | 一种催化加氢制备3‑甲基‑4‑氨基苯甲酸的方法 |
| US12240855B2 (en) | 2019-03-06 | 2025-03-04 | Daiichi Sankyo Company, Limited | Pyrrolopyrazole derivative |
| CN115010621B (zh) * | 2022-07-21 | 2023-11-03 | 山东百启生物医药有限公司 | 一种4-溴-3-甲基苯甲腈的合成方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996031497A1 (en) * | 1995-04-07 | 1996-10-10 | Novo Nordisk A/S | Novel heterocyclic compounds |
| RU2177473C2 (ru) * | 1996-05-14 | 2001-12-27 | Италфармако С.П.А. | Соединения, обладающие противовоспалительной и иммунодепрессивной активностью и содержащие их фармацевтические композиции |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL48807A0 (en) | 1975-02-18 | 1976-03-31 | Syntex Inc | Novel 6,11-dihydrodibenzo-thiepin-11-ones,their preparation and compositions containing them |
| US4130654A (en) * | 1978-01-30 | 1978-12-19 | Syntex (U.S.A.) Inc. | Novel 4-(8X-6,11-dihydrodibenzo-[b.e.]-thiepin-11-one-3-yl)-4-oxobutyric acids, methods of preparation, compositions and uses thereof |
| IL57077A0 (en) * | 1978-04-21 | 1979-07-25 | Syntex Inc | 6,11-dihydrodibenzo-thiepin-11-one s-oxides their preparation and pharmaceutical compositions containing them |
| GB2094790B (en) * | 1981-03-13 | 1985-10-09 | Spofa Vereinigte Pharma Werke | Tricycle compounds |
| JPH0240662A (ja) | 1988-08-01 | 1990-02-09 | Ricoh Co Ltd | 電子写真用感光体 |
| US5036067A (en) * | 1990-03-14 | 1991-07-30 | Merck & Co., Inc. | Dibenzoheterocyclic hydroxamic acids and hydroxy ureas as inhibitors of 5-lipoxygenase |
| JPH08119920A (ja) | 1994-10-18 | 1996-05-14 | Kyowa Hakko Kogyo Co Ltd | 三環式アニリド誘導体 |
| JPH0940662A (ja) | 1995-05-24 | 1997-02-10 | Kyowa Hakko Kogyo Co Ltd | 三環式化合物 |
| JPH11130772A (ja) | 1997-10-28 | 1999-05-18 | Kyowa Hakko Kogyo Co Ltd | 含窒素複素環化合物 |
| US6372779B1 (en) | 1997-12-29 | 2002-04-16 | Ortho Pharmaceutical Corporation | Anti-inflammatory compounds |
| TW200614995A (en) * | 2004-11-10 | 2006-05-16 | Nicholas Piramal India Ltd | Tricyclic guanidine derivatives as sodium-proton exchange inhibitors |
-
2005
- 2005-10-31 TW TW094138179A patent/TW200615273A/zh unknown
- 2005-11-08 EP EP05801266A patent/EP1812419A2/en not_active Withdrawn
- 2005-11-08 NZ NZ554937A patent/NZ554937A/en not_active IP Right Cessation
- 2005-11-08 US US11/667,580 patent/US7834052B2/en not_active Expired - Fee Related
- 2005-11-08 CN CN2005800426605A patent/CN101076525B/zh not_active Expired - Fee Related
- 2005-11-08 AU AU2005303410A patent/AU2005303410B2/en not_active Ceased
- 2005-11-08 JP JP2007540782A patent/JP2008519824A/ja not_active Ceased
- 2005-11-08 CA CA002587671A patent/CA2587671A1/en not_active Abandoned
- 2005-11-08 KR KR1020077013140A patent/KR20070106981A/ko not_active Ceased
- 2005-11-08 WO PCT/IB2005/053654 patent/WO2006051477A2/en not_active Ceased
- 2005-11-08 RU RU2007121682/04A patent/RU2406724C2/ru not_active IP Right Cessation
- 2005-11-08 MX MX2007005470A patent/MX2007005470A/es active IP Right Grant
- 2005-11-10 AR ARP050104716A patent/AR056861A1/es not_active Application Discontinuation
-
2007
- 2007-05-07 IL IL183038A patent/IL183038A0/en not_active IP Right Cessation
- 2007-05-07 IL IL210036A patent/IL210036A0/en unknown
- 2007-05-08 ZA ZA200703712A patent/ZA200703712B/xx unknown
-
2010
- 2010-08-11 US US12/854,745 patent/US7964631B2/en not_active Expired - Fee Related
- 2010-08-11 US US12/854,761 patent/US8163730B2/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996031497A1 (en) * | 1995-04-07 | 1996-10-10 | Novo Nordisk A/S | Novel heterocyclic compounds |
| RU2177473C2 (ru) * | 1996-05-14 | 2001-12-27 | Италфармако С.П.А. | Соединения, обладающие противовоспалительной и иммунодепрессивной активностью и содержащие их фармацевтические композиции |
Non-Patent Citations (1)
| Title |
|---|
| ACKRELL JACK ET AL, JOURNAL OF MEDICINAL CHEMISTRY, 21(10), pages 1035-1044, 1978. SINDELAR KAREL ET AL, COLLECTION OF CZECHOSLOVAK CHEMICAL COMMUNICATIONS, vol.50, 1985, pages 1485-1496. SINDELAR KAREL ET AL, COLLECTION OF CZECHOSLOVAK CHEMICAL COMMUNICATIONS, vol.49, 1984, pages 2531-2540. * |
Also Published As
| Publication number | Publication date |
|---|---|
| US7834052B2 (en) | 2010-11-16 |
| CN101076525A (zh) | 2007-11-21 |
| US8163730B2 (en) | 2012-04-24 |
| AU2005303410B2 (en) | 2011-12-15 |
| EP1812419A2 (en) | 2007-08-01 |
| CN101076525B (zh) | 2011-07-27 |
| MX2007005470A (es) | 2007-07-10 |
| ZA200703712B (en) | 2010-04-28 |
| IL210036A0 (en) | 2011-02-28 |
| NZ554937A (en) | 2011-01-28 |
| WO2006051477A2 (en) | 2006-05-18 |
| US20100305094A1 (en) | 2010-12-02 |
| CA2587671A1 (en) | 2006-05-18 |
| US20100324026A1 (en) | 2010-12-23 |
| IL183038A0 (en) | 2007-09-20 |
| JP2008519824A (ja) | 2008-06-12 |
| AU2005303410A1 (en) | 2006-05-18 |
| WO2006051477A3 (en) | 2006-08-03 |
| KR20070106981A (ko) | 2007-11-06 |
| TW200615273A (en) | 2006-05-16 |
| US7964631B2 (en) | 2011-06-21 |
| US20070299050A1 (en) | 2007-12-27 |
| RU2007121682A (ru) | 2008-12-20 |
| AR056861A1 (es) | 2007-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2007121682A (ru) | Конденсированные трициклические соединения в качестве ингибиторов фактора некроза опухоли альфа | |
| RU2315772C2 (ru) | Производные пептидов, содержащие тиазепиновую группу, для лечения гиперлипемических состояний | |
| US4225617A (en) | Acetohydroxamic acids | |
| RU2003127734A (ru) | Ингибиторы металлопротеиназ | |
| JP2004523581A5 (enExample) | ||
| CY1112835T1 (el) | Ενωσεις κιναζολινης | |
| RU2336276C2 (ru) | Пиперидиновые производные и способ их получения, применения, фармацевтическая композиция на их основе и способ лечения | |
| CA2344290A1 (en) | Quinazoline derivatives | |
| RU2001124567A (ru) | Производные индола и их применение в качестве антагонистов мср-1 | |
| RU2006127440A (ru) | Пиррольные и пиразольные ингибиторы daao | |
| JP2008519824A5 (enExample) | ||
| FR2540871A1 (fr) | Amino-2 phenyl-5 benzodiazepines-1,3; procede de preparation et medicaments les contenant | |
| RU96102670A (ru) | Производные 1,5-бензодиазепина | |
| ATE265998T1 (de) | Propancarbonsäure-amidoxim derivate, ein verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die diese entahlten | |
| RU2002132900A (ru) | Способ получения 3,3-диарилпропиламинов | |
| RU2006130866A (ru) | Новые спиропентациклические соединения | |
| DE3762860D1 (de) | 2-thiazolylimidazo(1,2-a)pyrimidine und ihre salze, verfahren zu ihrer herstellung, ihre anwendung als arzneimittel und diese enthaltende zubereitungen. | |
| RU2004114229A (ru) | Применение гидроксиолеиновой кислоты и родственных соединений при производстве лекарственных средств | |
| ATE402707T1 (de) | Imidazoä1,5aütriazoloä1,5dübenzodiazepin- derivative zur behandlung kognitiver störungen | |
| RU2007101497A (ru) | Алкилзамещенные индолхиноксалины | |
| AR023914A1 (es) | Caprolactamas sustituidas, un proceso para su preparacion, composiciones farmaceuticas que las contienen, y su uso para la preparacion de composicionesfarmaceuticas en el tratamiento de tumores | |
| DK0732332T3 (da) | Substituerede benzothienylpiperaziner, deres anvendelse som lægemidler og fremgangsmåder til fremstilling deraf | |
| RU2007132179A (ru) | Ингибирующие вич производные 2-(4-цианофениламино)пиримидина | |
| CZ20001367A3 (cs) | Způsob výroby chlorpurinových derivátů | |
| RU2004120065A (ru) | Антагонисты vii рецептора ccr-3 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC43 | Official registration of the transfer of the exclusive right without contract for inventions |
Effective date: 20130821 |
|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20131109 |